News

Article

Pharmaceutical Technology

Pharmaceutical Technology-04-15-2014
Volume2014 eBook
Issue 1

Selection of Excipients in Generic Formulations

Author(s):

Aloka Srinivasan

The selection of excipients is important in generic formulations due to the impact it has on the risk and performance of generic drugs.

The selection of excipients is important in generic formulations due to the impact it has on the risk and performance of generic drugs.

Download

Pharmaceutical Technology’s 2014 Solid Dosage and Excipients eBook

.

 

 

 

 

 

 

 

 

Articles in this issue
PTe0414_Colorcon.jpg
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
PTe0414_controlled.jpg
Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators
pte0414_hausnervideo.jpg
Continuous Manufacturing for Solid-Dosage Drug Production
PTe0414_Hovione.jpg
A Practical Guide to Hot-Melt Extrusion Scale-Up for Pharmaceutical Applications
PTe0414_ModWave.jpg
Using Modular Systems in Solid-Dosage Manufacturing
pte0414_Martinvideo.jpg
Advances in Hot-Melt Extrusion Manufacturing
PTe0414_Bohle.jpg
Obtaining User-Defined Particle Size Distribution Using Dry Granulation
PTe0414_evonik.jpg
A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
PTe0414Generic.jpg
Selection of Excipients in Generic Formulations

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
July 25th 2025

EMA Approves Lower GWP Alternative for Inhalation Medicine

Susan Haigney
The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava Aerosphere that will have a 1000-fold reduction in global warming potential compared to the current propellant.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
June 25th 2024

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Magnifier with pills on blue background | Image Credit: © Pixel-Shot - stock.adobe.com
July 23rd 2025

Overcoming PK/PD Modeling Challenges

Cynthia A. Challener
Artificial intelligence and machine learning can help identify complex patterns.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com
July 22nd 2025

AstraZeneca to Invest $50 Billion in US Manufacturing and R&D

Susan Haigney
The company will build a multi-billion-dollar drug manufacturing center in Virginia that will focus on chronic diseases, as well as facilities in California, Indiana, Maryland, Massachusetts, and Texas.
Rueil-Malmaison, France - 13 août 2023: Siège social France de Bristol-Myers Squibb, entreprise pharmaceutique américaine née de la fusion entre Bristol-Myers Company et Squibb Corporation | Image Credit: © HJBC - stock.adobe.com
July 22nd 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery
Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.